Dr. Schlossman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
40 Landsdowne Street
Cambridge, MA 02139Phone+1 857-600-3421- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1992 - 1995
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1992
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1988 - 1991
Tufts University School of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1992 - 2025
NY State Medical License 1989 - 1992
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma Start of enrollment: 2008 May 01
- Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.McMillin, D., Delmore, J., Weisberg, E., Negri, J., Geer, C., Klippel, S., Munshi, N., Mitsiades, C., Mitsiades, N., Schlossman, R., Kung, A., Griffin, J., Richardson,...> ;Nature Medicine. 2024 Feb 14
- 1 citationsRisk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.Matthew Ho, Maria Moscvin, Soon Khai Low, Benjamin Evans, Sara Close, Robert Schlossman, Jacob Laubach, Claudia Paba Prada, Brett Glotzbecker, Paul G Richardson, Giada...> ;Leukemia & Lymphoma. 2022 Oct 1
- 42 citationsFunctional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.Ryosuke Shirasaki, Geoffrey M. Matthews, Sara Gandolfi, Ricardo De Matos Simoes, Dennis L. Buckley, Joseline Raja Vora, Quinlan L. Sievers, Johanna Bruggenthies, Olga ...> ;Cell Reports. 2021 Jan 5
- Join now to see all
Abstracts/Posters
- Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...Robert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of OncoproteinsRobert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Robert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Salem HospitalSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
